A randomized surgical window-of-opportunity trial found that giving dual immune checkpoint blockade before resection improved immune infiltration in recurrent glioblastoma, with signals toward longer survival. The results were published in Nature Communications. The study assessed how preoperative therapy remodeled tumor immunity during the interval before surgery, reporting measurable changes in T-cell infiltration and immune activity within the tumor microenvironment. By correlating those immune shifts with clinical outcomes, the authors argue for a mechanistic link between early immune engagement and longer-term disease control. For glioblastoma stakeholders, the report adds to evidence that timing—pre-surgical rather than post-surgical sequencing—can materially change the immune biology that therapies encounter.